Inhibitors of metallo-β-lactamases

Current Opinion in Microbiology

Volumn 39, Issue , 2017, Pages 96-105

  Rotondo, Caitlyn M ^a   Wright, Gerard D ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BETA LACTAMASE INHIBITOR; METALLO BETA LACTAMASE; ZINC; ANTIINFECTIVE AGENT; BETA LACTAM;

ACINETOBACTER BAUMANNII; ENZYME INHIBITION; ENZYME MECHANISM; ENZYME STRUCTURE; HUMAN; NONHUMAN; PROVIDENCIA RETTGERI; REVIEW; ANIMAL; BACTERIAL INFECTION; BACTERIUM; DISEASE MODEL; DRUG EFFECTS; ENZYMOLOGY; MICROBIOLOGY;

ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIA; BACTERIAL INFECTIONS; BETA-LACTAMASE INHIBITORS; BETA-LACTAMS; DISEASE MODELS, ANIMAL; HUMANS;

EID: 85034094152     PISSN: 13695274     EISSN: 18790364     Source Type: Journal    
DOI: 10.1016/j.mib.2017.10.026     Document Type: Review

References (50)

1. Landan, G., Cohen, G., Aharonowitz, Y., Shuali, Y., Graur, D., Shiffman, D., Evolution of isopenicillin N synthase genes may have involved horizontal gene transfer. Mol Biol Evol 7 (1990), 399–406.
2. Fisher, J.F., Meroueh, S.O., Mobashery, S., Bacterial resistance to β-lactam antibiotics: compelling opportunism, compelling opportunity. Chem Rev 105 (2005), 395–424.
3. King, D.T., Sobhanifar, S., Strynadka, N.C.J., One ring to rule them all: current trends in combating bacterial resistance to the β-lactams. Protein Sci 25 (2016), 787–803 Excellent review of the molecular spectrum of β-lactam resistance.
4. Li, X-Z., Plésiat, P., Nikaido, H., The challenge of efflux-mediated antibiotic resistance in Gram-negative bacteria. Clin Microbiol Rev 28 (2015), 337–418.
5. Nikaido, H., Pagès, J-M., Broad-specificity efflux pumps and their role in multidrug resistance of Gram-negative bacteria. FEMS Microbiol Rev 36 (2012), 340–363.
6. Fishovitz, J., Hermoso, J.A., Chang, M., Mobashery, S., Penicillin-binding protein 2a of methicillin-resistant Staphylococcus aureus. IUBMB Life 66 (2014), 572–577.
7. Papp-Wallace, K.M., Bonomo, R.A., New β-lactamase inhibitors in the clinic. Infect Dis Clin North Am 30 (2016), 441–464.
8. Bush, K., A resurgence of β-lactamase inhibitor combinations effective against multidrug-resistant Gram-negative pathogens. Int J Antimicrob Agents 46 (2015), 483–493.
9. Khan, A.U., Maryam, L., Zarrilli, R., Structure, genetics and worldwide spread of New Delhi Metallo-β-lactamase (NDM): a threat to public health. BMC Microbiol, 17, 2017, 101.
10. Dortet, L., Poirel, L., Nordmann, P., Worldwide dissemination of the NDM-type carbapenemases in Gram-negative bacteria. Biomed Res Int, 2014, 2014, 249856.
11. Chen, L., Todd, R., Kiehlbauch, J., Walters, M., Kallen, A., Notes from the field: pan-resistant New Delhi Metallo-beta-lactamase-producing Klebsiella pneumoniae — Washoe County, Nevada, 2016. MMWR Morb Mortal Wkly Rep, 66, 2017, 33.
12. Poirel, L., Kieffer, N., Liassine, N., Thanh, D., Plasmid-mediated carbapenem and colistin resistance in a clinical isolate of Escherichia coli. Lancet Infect Dis, 16, 2016, 281.
13. Palzkill, T., Metallo-β-lactamase structure and function. Ann N Y Acad Sci 1277 (2013), 91–104 Comprehensive overview of MLB structure and function.
14. Sánchez, M.B., Antibiotic resistance in the opportunistic pathogen Stenotrophomonas maltophilia. Front Microbiol, 6, 2015, 658.
15. González, L.J., Vila, A.J., Carbapenem resistance in Elizabethkingia meningoseptica is mediated by metallo-β-lactamase BlaB. Antimicrob Agents Chemother 56 (2012), 1686–1692.
16. Mojica, M.F., Bonomo, R.A., Fast, W., B1-metallo-β-lactamases: where do we stand?. Curr Drug Targets 17 (2016), 1029–1050 Insightful and comprehensive review on MBL structure, diversity and distribution.
17. NDM-1, and a novel erythromycin esterase gene carried on a unique genetic structure in Klebsiella pneumoniae sequence type 14 from India. Antimicrob Agents Chemother 53 (2009), 5046–5054.
18. Berrazeg, M., Diene, S., Medjahed, L., Parola, P., Drissi, M., Raoult, D., Rolain, J., New Delhi Metallo-beta-lactamase around the world: an eReview using Google Maps. Euro Surveill, 19, 2014.
19. World Health Organization, Global Priority List of Antibiotic-Resistant Bacteria to Guide Research, Discovery, and Development of New Antibiotics. 2017.
20. Pettinati, I., Brem, J., Lee, S.Y., McHugh, P.J., Schofield, C.J., The chemical biology of human metallo-β-lactamase fold proteins. Trends Biochem Sci 41 (2016), 338–355.
21. Crowder, M.W., Spencer, J., Vila, A.J., Metallo-beta-lactamases: novel weaponry for antibiotic resistance in bacteria. Acc Chem Res 39 (2006), 721–728.
22. Galleni, M., Lamotte-Brasseur, J., Rossolini, G.M., Spencer, J., Dideberg, O., Frere, J.M., Metallo-beta-lactamases Working Group. Standard numbering scheme for class B beta-lactamases. Antimicrob Agents Chemother 45 (2001), 660–663.
23. Li, G-B., Abboud, M.I., Brem, J., Someya, H., Lohans, C.T., Yang, S-Y., Spencer, J., Wareham, D.W., McDonough, M.A., Schofield, C.J., NMR-filtered virtual screening leads to non-metal chelating metallo-β-lactamase inhibitors. Chem Sci 8 (2017), 928–937 First report of non-metal interacting MBL inhibitors.
24. Meini, M-R., González, L.J., Vila, A.J., Antibiotic resistance in Zn(II)-deficient environments: metallo-β-lactamase activation in the periplasm. Future Microbiol 8 (2013), 947–979.
25. Cerasi, M., Ammendola, S., Battistoni, A., Competition for zinc binding in the host-pathogen interaction. Front Cell Infect Microbiol, 3, 2013, 10.3389/fcimb.2013.00108/abstract.
26. Faridoon, Ul Islam, N., An update on the status of potent inhibitors of metallo-β-lactamases. Sci Pharm 81 (2013), 309–327.
27. Klingler, F-M., Wichelhaus, T.A., Frank, D., Cuesta-Bernal, J., El-Delik, J., Müller, H.F., Sjuts, H., Göttig, S., Koenigs, A., Pos, K.M., et al. Approved drugs containing thiols as inhibitors of metallo-β-lactamases: strategy to combat multidrug-resistant bacteria. J Med Chem 58 (2015), 3626–3630.
28. Brem, J., van Berkel, S.S., Zollman, D., Lee, S.Y., Gileadi, O., McHugh, P.J., Walsh, T.R., McDonough, M.A., Schofield, C.J., Structural basis of metallo-β-lactamase inhibition by captopril stereoisomers. Antimicrob Agents Chemother 60 (2015), 142–150 Comprehensive chemical synthesis, enzymatic analysis, structural validation and microbiological study of MBL inhibition by captopril diastereomers.
29. García-Saez, I., Hopkins, J., Papamicael, C., Franceschini, N., Amicosante, G., Rossolini, G.M., Galleni, M., Frère, J-M., Dideberg, O., The 1.5-A structure of Chryseobacterium meningosepticum zinc beta-lactamase in complex with the inhibitor, D-captopril. J Biol Chem 278 (2003), 23868–23873.
30. Brem, J., van Berkel, S.S., Aik, W., Rydzik, A.M., Avison, M.B., Pettinati, I., Umland, K-D., Kawamura, A., Spencer, J., Claridge, T.D.W., et al. Rhodanine hydrolysis leads to potent thioenolate mediated metallo-β-lactamase inhibition. Nat Chem 6 (2014), 1084–1090.
31. González, M.M., Kosmopoulou, M., Mojica, M.F., Castillo, V., Hinchliffe, P., Pettinati, I., Brem, J., Schofield, C.J., Mahler, G., Bonomo, R.A., et al. Bisthiazolidines: a substrate-mimicking scaffold as an inhibitor of the NDM-1 carbapenemase. ACS Infect Dis 1 (2015), 544–554 Rational discovery of a new class of MBL inhibitor.
32. Hinchliffe, P., González, M.M., Mojica, M.F., González, J.M., Castillo, V., Saiz, C., Kosmopoulou, M., Tooke, C.L., Llarrull, L.I., Mahler, G., et al. Cross-class metallo-β-lactamase inhibition by bisthiazolidines reveals multiple binding modes. Proc Natl Acad Sci U S A 113 (2016), E3745–E3754.
33. Zhai, L., Zhang, Y-L., Kang, J.S., Oelschlaeger, P., Xiao, L., Nie, S-S., Yang, K-W., Triazolylthioacetamide: a valid scaffold for the development of New Delhi Metallo-β-lactmase-1 (NDM-1) Inhibitors. ACS Med Chem Lett 7 (2016), 413–417.
34. Yang, S-K., Kang, J.S., Oelschlaeger, P., Yang, K-W., Azolylthioacetamide: a highly promising scaffold for the development of metallo-β-lactamase inhibitors. ACS Med Chem Lett 6 (2015), 455–460.
35. Christopeit, T., Yang, K.W., Yang, S.K., Leiros, H.K.S., The structure of the metallo-β-lactamase VIM-2 in complex with a triazolylthioacetamide inhibitor. Acta Cryst 72 (2016), 1–7.
36. Christopeit, T., Leiros, H-K.S., Fragment-based discovery of inhibitor scaffolds targeting the metallo-β-lactamases NDM-1 and VIM-2. Bioorg Med Chem Lett 26 (2016), 1973–1977.
37. Christopeit, T., Carlsen, T.J.O., Helland, R., Leiros, H-K.S., Discovery of novel inhibitor scaffolds against the metallo-β-lactamase VIM-2 by surface plasmon resonance (SPR) based fragment screening. J Med Chem 58 (2015), 8671–8682.
38. Christopeit, T., Albert, A., Leiros, H-K.S., Discovery of a novel covalent non-β-lactam inhibitor of the metallo-β-lactamase NDM-1. Bioorg Med Chem 24 (2016), 2947–2953.
39. Hecker, S.J., Reddy, K.R., Totrov, M., Hirst, G.C., Lomovskaya, O., Griffith, D.C., King, P., Tsivkovski, R., Sun, D., Sabet, M., et al. Discovery of a cyclic boronic acid β-lactamase inhibitor (RPX7009) with utility vs class A serine carbapenemases. J Med Chem 58 (2015), 3682–3692.
40. Rojas, L.J., Taracila, M.A., Papp-Wallace, K.M., Bethel, C.R., Caselli, E., Romagnoli, C., Winkler, M.L., Spellberg, B., Prati, F., Bonomo, R.A., Boronic acid transition state inhibitors active against KPC and other class A β-lactamases: structure–activity relationships as a guide to inhibitor design. Antimicrob Agents Chemother 60 (2016), 1751–1759.
41. Brem, J., Cain, R., Cahill, S., McDonough, M.A., Clifton, I.J., Jiménez-Castellanos, J-C., Avison, M.B., Spencer, J., Fishwick, C.W.G., Schofield, C.J., Structural basis of metallo-β-lactamase, serine-β-lactamase and penicillin-binding protein inhibition by cyclic boronates. Nat Commun, 7, 2016, 12406 Demonstration of efficacy and molecular analysis of cyclic-boronate inhibitors of MBLs.
42. Somboro, A.M., Tiwari, D., Bester, L.A., Parboosing, R., Chonco, L., Kruger, H.G., Arvidsson, P.I., Govender, T., Naicker, T., Essack, S.Y., NOTA: a potent metallo-β-lactamase inhibitor. J Antimicrob Chemother 70 (2015), 1594–1596.
43. Falconer, S.B., Reid-Yu, S.A., King, A.M., Gehrke, S.S., Wang, W., Britten, J.F., Coombes, B.K., Wright, G.D., Brown, E.D., Zinc chelation by a small-molecule adjuvant potentiates meropenem activity in vivo against NDM-1-producing Klebsiella pneumoniae. ACS Infect Dis 1 (2015), 533–543.
44. King, A.M., Reid-Yu, S.A., Wang, W., King, D.T., De Pascale, G., Strynadka, N.C., Walsh, T.R., Coombes, B.K., Wright, G.D., Aspergillomarasmine A overcomes metallo-β-lactamase antibiotic resistance. Nature 510 (2014), 503–506 First report of a natural product MBL inactivator demonstrating efficacy in vitro and in vivo.
45. Haenni, A.L., Robert, M., Vetter, W., Roux, L., Barbier, M., Lederer, E., Structure chimique des aspergillomarasmines A et B. Helv Chim Acta 48 (1965), 729–750.
46. Mikami, Y., Suzuki, T., Novel microbial inhibitors of angiotensin-converting enzyme, aspergillomarasmines A and B. Agric Biol Chem 47 (1983), 2693–2695.
47. Arai, K., Ashikawa, N., Nakakita, Y., Aspergillomarasmine A and B, potent microbial inhibitors of endothelin-converting enzyme. Bioscience 57 (1993), 1944–1945.
48. Liao, D., Yang, S., Wang, J., Zhang, J., Hong, B., Wu, F., Lei, X., Total synthesis and structural reassignment of aspergillomarasmine A. Angew Chem Int Ed Engl 55 (2016), 4291–4295.
49. Albu, S.A., Koteva, K., King, A.M., Al-Karmi, S., Wright, G.D., Capretta, A., Total synthesis of aspergillomarasmine A and related compounds: a sulfamidate approach enables exploration of structure–activity relationships. Angew Chem 55 (2016), 13259–13262.
50. Koteva, K., King, A.M., Capretta, A., Total synthesis and activity of the metallo-β-lactamase inhibitor aspergillomarasmine A. Angew Chem 55 (2016), 2210–2212.